Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

ACADIA P Form 4 March 24, 2	HARMACEUTIC	CALS INC								
FORM	Π Δ								PPROVA	۱L
	UNITED	STATES		RITIES A			COMMISSION	N OMB Number:	3235-	0287
Check th if no lon subject t Section Form 4 o	ger STATEN o STATEN 16. or			SECU	WNERSHIP OF	Estimated burden hoi response	average urs per	ry 31, 2005 0.5		
Form 5 obligatio may con <i>See</i> Instr 1(b).	tinue. Section 17	a) of the I	Public U	Itility Hol	ding Coi		nge Act of 1934, of 1935 or Section 940			
(Print or Type	Responses)									
1. Name and A Baity Glenn	2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS			5. Relationship of Reporting Person(s) to Issuer						
	INC [A		MACEU	IICALS	(Check all applicable)					
(Last) (First) (Middle) 3611 VALLEY CENTRE DRIVE,			3. Date of Earliest Transaction (Month/Day/Year) 03/20/2015			Director 10% Owner Officer (give title Other (specify below) below) EVP AND GC				
SUITE 300	1									
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 				
SAN DIEG	O, CA 92130							More than One R		
(City)	(State)	(Zip)	Tat	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	illy Owned	d
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect Beneficia Ownershi (Instr. 4)	al ip
Reminder: Rej	port on a separate line	e for each cla	ass of sec	urities benet	ficially ow	ned directly	or indirectly.			
					inforr requi	nation cont red to resp ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab					posed of, or convertible	Beneficially Owned securities)	1		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/	(Year)	(Instr. 3 and 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 34.45	03/20/2015		А		120,000		<u>(1)</u>	03/19/2025	Common Stock	120,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Baity Glenn 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO, CA 92130			EVP AND GC				
Signatures							

/s/ Glenn F. Baity	03/24/2015			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to the Stock Option vest and become exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.